Wondering if semaglutide is only for diabetes? Learn how licensed providers may consider it for metabolic wellness in eligible patients.
Semaglutide has become a widely discussed medication in health and wellness spaces. Initially approved by the FDA for managing blood sugar in individuals with type 2 diabetes, it has also received approval under a different brand name for chronic weight management in certain individuals.
This has led many people to ask: Can semaglutide be considered by licensed healthcare providers for individuals who are not diabetic but are pursuing metabolic wellness goals?
In some cases, the answer may be yes. Licensed healthcare providers on the Eden platform may evaluate whether semaglutide is appropriate for individuals based on body composition, health history, and wellness goals.
Semaglutide is approved by the FDA under the brand name Ozempic® for treating type 2 diabetes and as Wegovy® for chronic weight management in adults with obesity or those who are overweight and have a qualifying weight-related condition.
Though developed for blood sugar control, semaglutide has also been studied in populations without diabetes for its role in supporting weight-related outcomes. These findings have led to greater interest in its potential applications in metabolic wellness programs.
A diabetes diagnosis is not required for eligibility under FDA-approved uses. Adults who are overweight or have obesity and meet other clinical criteria may be evaluated by a licensed provider for treatment options involving semaglutide.
Conditions that may be considered during evaluation include:
Eligibility is based on a comprehensive assessment conducted by a licensed provider, not just a diagnosis.
{{primary-cta}}
Eden is a digital health platform that simplifies access to care by connecting individuals with independent, licensed healthcare providers. These providers specialize in evidence-based treatment programs tailored to metabolic wellness goals.
The process is simple:
Only a licensed healthcare provider can determine whether semaglutide may be an option for you. If you're considering support for body composition or other metabolic health goals, a provider will evaluate your eligibility based on:
The Eden platform provides a confidential and supportive way to explore this option under professional guidance.
{{primary-cta}}
While semaglutide is FDA-approved for specific uses in type 2 diabetes and weight management, licensed healthcare providers may consider it for eligible individuals without diabetes as part of a personalized wellness plan.
Eden helps individuals access care from independent providers who review your health history and goals to determine whether GLP-1 treatment may be appropriate for you.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
